Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
LLY compared with VRXA: revenue, margins and what each company keeps, and the suppliers and customers both name
LLY
ELI Lilly & Co
Change
Mkt cap
Revenue
Revenue
VRXA
Veraxa Biotech AG - Post de-SPAC
Change
Mkt cap
Revenue
Revenue
vs
Compare
LLY
ELI Lilly & Co
vs
VRXA
Veraxa Biotech AG - Post de-SPAC
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Event sensitivity
Desk
News
Calendar
Saved
Search
Event sensitivity
release-day history · min 6 releases
Method
›
Insufficient release history: VRXA.
LLY
ELI Lilly & Co
Change
1,371.32
▼
−3.29%
· post 1,359.00
· delayed
Mkt cap
$1.3T
Revenue
$24.4B
Q3 FY26
Revenue
$65.2B
FY25
VRXA
Veraxa Biotech AG - Post de-SPAC
Change
0.98
▲
+3.25%
· post 0.98
· delayed
After hours
Nov 5 '26
delayed
Mkt cap
$13.8M
Revenue
—
Revenue
—
vs
Compare
After hours
Nov 5 '26
delayed
LLY
ELI Lilly & Co
vs
VRXA
Veraxa Biotech AG - Post de-SPAC
1,371.32
▼
−3.29%
post 1,359.00
delayed
Price
0.98
▲
+3.25%
post 0.98
delayed
$1.3T
Mkt cap
$13.8M
Q3 FY26
$24.4B
Revenue
—
FY25
$65.2B
Revenue
—
Change
Change
LLY
1,371.32
▼
−3.29%
vs
VRXA
0.98
▲
+3.25%
After hours
Nov 5 '26
delayed